» Articles » PMID: 15340372

The Epidemiology of Interstitial Lung Disease and Its Association with Lung Cancer

Overview
Journal Br J Cancer
Specialty Oncology
Date 2004 Sep 2
PMID 15340372
Citations 97
Authors
Affiliations
Soon will be listed here.
Abstract

The criteria and terminology for diagnosing interstitial lung disease (ILD), a diverse range of pulmonary fibrotic disorders that affect the alveoli of the lungs, have been variable and confusing; however, there have been recent major improvements to an internationally agreed classification. Evidence from recent analyses of populations suggests that the incidence and prevalence rates of ILD are on the increase, particularly when the broad definition of ILD is used. In most patients with ILD a cause is not identified; nevertheless, among the established causes are a number of drug therapies and infections. Occupational causes are lessening in importance, while cigarette smoking is now an established risk factor. Radiation therapy for cancer is a well-established cause of ILD that usually, but not always, localises within the radiation portal and may occur later after completion of therapy. Similarly, exposure to drugs long after radiation therapy may be an aetiological factor for the development of ILD later in life, although the magnitude of this risk requires further epidemiological investigation. The possibility that ILD and lung cancer are associated has been recognised for >50 years, but it remains unclear whether ILD precedes lung cancer or vice versa. In this review, we examine the epidemiology of ILD and the basis for its association with lung cancer.

Citing Articles

Metabolomics-based combination of GH and NVB in the treatment of NSCLC lung cancer recurrence.

Li X, Chen F, Yang R, Song Z, Ma X, Sun L J Cancer. 2025; 16(1):265-278.

PMID: 39744563 PMC: 11660129. DOI: 10.7150/jca.102722.


Perioperative Anti-Fibrotic Treatment Prevents Acute Exacerbation of Idiopathic Pulmonary Fibrosis After Lung Cancer Surgery.

Bongiolatti S, Salvicchi A, Rosi E, Bargagli E, Mugnaini G, Gonfiotti A Life (Basel). 2024; 14(11).

PMID: 39598304 PMC: 11595336. DOI: 10.3390/life14111506.


Long Term Evaluation of Quantitative Cumulative Irradiation in Patients Suffering from ILDs.

Berg J, Frix A, Henket M, Gester F, Winandy M, Canivet P Diagnostics (Basel). 2024; 14(19).

PMID: 39410540 PMC: 11476226. DOI: 10.3390/diagnostics14192136.


Novel prediction model of early screening lung adenocarcinoma with pulmonary fibrosis based on haematological index.

Li H, Fu X, Liu M, Chen J, Cao W, Liang Z BMC Cancer. 2024; 24(1):1178.

PMID: 39333995 PMC: 11438419. DOI: 10.1186/s12885-024-12902-6.


Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD): Update on Prevalence, Risk Factors, Pathogenesis, and Therapy.

Sullivan D, Ascherman D Curr Rheumatol Rep. 2024; 26(12):431-449.

PMID: 39320427 DOI: 10.1007/s11926-024-01155-8.


References
1.
Harris J, Cullinan P, McDonald J . Does cryptogenic fibrosing alveolitis carry an increased risk of death from lung cancer?. J Epidemiol Community Health. 1999; 52(9):602-3. PMC: 1756764. DOI: 10.1136/jech.52.9.602. View

2.
Aubry M, Myers J, Douglas W, Tazelaar H, Washington Stephens T, Hartman T . Primary pulmonary carcinoma in patients with idiopathic pulmonary fibrosis. Mayo Clin Proc. 2002; 77(8):763-70. DOI: 10.4065/77.8.763. View

3.
Hodgson U, Laitinen T, Tukiainen P . Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. Thorax. 2002; 57(4):338-42. PMC: 1746288. DOI: 10.1136/thorax.57.4.338. View

4.
Thomeer M, Demedts M, Vandeurzen K . Registration of interstitial lung diseases by 20 centres of respiratory medicine in Flanders. Acta Clin Belg. 2001; 56(3):163-72. DOI: 10.1179/acb.2001.026. View

5.
Hubbard R, Venn A, Lewis S, Britton J . Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med. 2000; 161(1):5-8. DOI: 10.1164/ajrccm.161.1.9906062. View